Searched for
CNS PORTFOLIO EXPANSION
Stocks in news: Fractal Analytics, RIL, Cochin Shipyard, Trent, BritanniaMarkets saw volatility but recovered modestly on Monday, with analysts maintaining a cautious outlook. Several stocks like Fractal Analytic...- Healthcare stocks: Better to own a collection? 16 stocks from different segments with upside potential of 10 to 35% in 1 yearBefore you read on, be clear about one thing. The stocks on our list today are expensive in terms of valuations and may well witness correc...
- Creador to buy 7% stake in pharma company La RenonCreador, a Kuala Lumpur-based private equity firm, is set to acquire a 7% stake in La Renon Healthcare for ₹800 crore, valuing the Indian p...
- Dr Reddy’s shares slip nearly 2% on investor concerns amid $50 million foray into anti-vertigo categoryDr. Reddy's Laboratories' shares experienced a slight dip following the announcement of their acquisition of Stugeron from Johnson & Johnso...
- Pharma stocks: Moving from ‘What if’ to ‘Maybe not’. 8 pharma stocks, 3 with upside potential above 22%; others not so high, but…There are two ways to look at the hope which the street is reflecting when it comes to a possible India-US tariff deal. One, it will bring ...
- Can Granules India leverage its strong product pipeline to offset recent profit declines?Granules India's stock shows a slight recovery despite reporting lower profits in the June quarter. Investors are positive about the compan...
- Volatile phases come and go, structural tailwinds are a stronger play: 5 Indian pharma stocks with upside potential of up to 35%There are some sectors which have witnessed something which can be called “second inning”. Which is that in the last two decades, they did ...
- The yen connection: 4 Indian pharma stocks which benefit from the strength of Japanese yen with an upside potential of up to 15%Every event in the currency market has a twin impact, while some lose but there are others which also gain. But given the mayhem on the str...
- Fundamental tailwinds are a stronger play than volatile markets? 5 Indian pharma stocks with upside potential of up to 31 %There is no doubt that the market is going through a volatile phase and bears are once again telling the street to never write them off. Wi...
- Intent of global acquisitions, has the tide turned for the long term? 5 pharma stocks with upside potential of up to 31 %Just yesterday, there was a news report which suggested that the French government is planning to block the sale of a French generic drug m...
- Fundamental tailwinds are a stronger play than volatile markets? 5 Indian pharma stocks with upside potential of up to 41%There is no doubt that the market is going through a volatile phase and bears are once again telling the street to never write them off. Wi...
- Ready for another round of re-rating even in a volatile market? 5 Indian pharma stocks with upside potential of up to 41%In the last two years, every sector has come into focus at one point of time or the other. Some came into limelight due to the fact of real...
- June sales surge for Pharma Inc as other therapies make up for a waning CovidThe Covid drug portfolio grew 8% in value while the value growth of non-Covid drugs stood at 21%. "The Covid drugs growth has come down and...
- 5 stocks that defied meltdown to log 300% gains in FY20Five stocks stood out from the BSE500; they defied the selloff to log 50-300 per cent gains.
- Arinna Lifesciences in to raise around Rs 75 crore in latest round of fundingArinna operates with 18 regional offices, more than 680 stockists and its’ products are sold in over 23 states across the county, the compa...
- Buy Sun Pharmaceutical Industries, target Rs 581: Nirmal Bang Institutional EquitiesBuy Sun Pharmaceutical Industries at a price target of Rs 581.
- Alkem Labs to tap domestic, international markets for growthIn the domestic market, the company plans to consolidate presence in the segments it is in and is aiming to build base in the emerging ther...
- Alkem Labs will continue to outperform the industry in next 18 months: Sandeep Singh, Director"I can't share any numbers at this point. But I can tell you that H1 was very nice, much better than last year. We expect this year to be a...
- Three blue-chip stocks to catch at reasonable price in ongoing market rallyFinding attractively valued blue-chip stocks has become difficult after the recent rally. Here are three stocks that are still reasonably p...
- Aurobindo to be on prowl again in EUAurobindo Pharma, which has made three acquisition in the EU this financial year, is looking for a string of small buyouts to double its re...
Load More
